{"entity":{"id":"r-pharm","kind":"company","name":"R-Pharm","aka":["R-Pharm JSC","Р-Фарм"],"tldr":"R-Pharm is a large private Russian pharmaceutical company that manufactures and licenses medicines including cancer generics and biosimilars, and sponsors phase 3 trials of them in Russia.","summary":"R-Pharm, founded in Moscow in 2001, is one of Russia's largest pharmaceutical companies, spanning manufacturing, distribution and development, including generic and biosimilar cancer medicines and licensed products for the Russian market. It appears as lead sponsor of a number of phase 3 cancer trials on ClinicalTrials.gov, mostly comparative studies of its versions of established drugs. OnCo records it so that those trials resolve to a sponsor page.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://r-pharm.com"},{"label":"ClinicalTrials.gov: trials led by R-Pharm","url":"https://clinicaltrials.gov/search?lead=R-Pharm"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/R-Pharm"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["rph-051"],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct07553988"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Moscow","country":"RU","companyType":"pharma","website":"https://r-pharm.com","stage":"private-large","investors":[],"funding":[]},"route":"/companies/r-pharm/","neighbours":{"drug":[{"id":"rph-051","kind":"drug","name":"RPH-051","route":"/drugs/rph-051/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}],"trial":[{"id":"nct07553988","kind":"trial","name":"A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer","route":"/trials/nct07553988/"},{"id":"nct00883116","kind":"trial","name":"A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer","route":"/trials/nct00883116/"},{"id":"nct07386938","kind":"trial","name":"A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer","route":"/trials/nct07386938/"}]}}